Alzheimer's and Parkinson's charities identify new ways to reuse current drugs
Experts say that by repurposing drugs, they can 'increase the shots on target' at tackling the diseases.
This method of drug development could also reduce the time patients are left waiting for new treatments by up to 10 years, they added.
It comes after the NHS spending watchdog rejected the use of new Alzheimer's drugs lecanemab and donanemab for widespread use in the health service.
The drugs were approved for use in the UK last year by the UK's medicines regulator but the NHS spending watchdog, the National Institute for Health and Care Excellence (Nice), said they could not be used in the NHS because the benefits are 'too small' to justify the cost.
Now charities Cure Parkinson's and Alzheimer's Research UK have joined forces to find current drugs that may tackle some of the common biology behind both diseases.
https://x.com/AlzResearchUK/status/1929856926885539966/photo/2
After presentations to the International Linked Clinical Trials (iLCT), which was set up by Cure Parkinson's over a decade ago, experts from both fields will select the most promising drugs for both Parkinson's and dementia, so they can be moved quickly into clinical trials.
Weight loss jabs are already being investigated for their effectiveness in treating symptoms of both diseases and experts hope to uncover more drugs that can have multiple uses.
Semaglutide, the active ingredient for weight loss and diabetes drugs Wegovy and Ozempic, is being examined in clinical trials to see whether it can help patients with Alzheimer's disease or Parkinson's.
Trial results for the Alzheimer's trial are expected to be published later this year.
Dr Sheona Scales, director of research at Alzheimer's Research UK, told the PA news agency that the iLCT project had already been 'hugely successful' with people who have Parkinson's, adding: 'Around 30% of disease modifying therapies that are in clinical trials for Parkinson's disease came through this process.
'What we wanted to do is to build on their knowledge and experience and expertise in order to be able to bring a process similar to that to Alzheimer's disease.'
Dr Scales said that there are some 'common grounds' between Parkinson's and Alzheimer's – both are neurodegenerative diseases and have some 'common biological processes' – such as inflammation, mitochondrial dysfunction and 'protein misfolding' – which could be targets for repurposed drugs.
'Getting multiple drugs that are targeting the disease is really important to us,' she said.
'Testing different types of drugs and getting as many shots on target is important.'
She said: 'Repurposed drugs have already been demonstrated to be safe for use in humans development of new drugs for different diseases is a long process.
'What essentially bringing repurposed drugs does, is help to accelerate the drug development pipeline – it could save between five and 10 years within that process, compared to taking a new drug through clinical trials for the very first time.'
Helen Matthews, chief executive of Cure Parkinson's, said the iLCT was originally set up to identify drugs that can potentially 'slow down, stop or reverse Parkinson's'.
She added: 'It was through this programme that we realised that there were so many drugs that were also being looked at in the dementia field and there were commonalities there in terms of the drugs looking to reduce inflammation, or whatever it might be, there were specific pathways that those drugs were working on that could be beneficial for both disease areas.
'So given that we were already doing the (work) every year, it made sense to join forces in this way, just to add efficiencies.
'Because if you're looking at the same drugs, we'll only do that digging once, you know, only do that compilation of the dossiers once, so that you can actually take the learning for both diseases and then actually look and see which might be beneficial.'
She said that the 'sharing of knowledge and digging' could also be shared with other disease areas, such as MS.
And on lecanemab and donanemab, Dr Scales added: '(These) were the first disease-targeting therapies that have been licensed in the UK, but obviously are not available on the NHS at the moment.
'They showed for the very first time that we were able to alter the course of the disease.
'And what we're looking forward to now is what the next generation of treatments can bring us and how we can target different parts of the disease.'
Dr Lucy Devendra, head of research at Alzheimer's Society, said: 'Repurposing medicines which are already known to be safe can help us find new treatments for the diseases that cause dementia much quicker.
'Although it is still early days, it's encouraging to see a renewed focus on this type of research and development.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Powys County Times
an hour ago
- Powys County Times
Chris Hoy calls for systemic change in testing for prostate cancer
Six-time Olympic champion Sir Chris Hoy has called for systemic change in the ways men get tested for prostate cancer. The 49-year old cyclist was diagnosed with stage four prostate cancer in 2023 and was told last year that it has spread to his bones and is terminal. NHS guidance says men over the age of 50 are at highest risk of developing prostate cancer, but Sir Chris wants to help men get screened earlier. He said: 'I was diagnosed with stage four prostate cancer at 47. By this age, my prostate cancer was advanced and could have been progressing from when I was 45 or even younger. 'With prostate cancer, the earlier you find it, the easier it is to treat. We need the system to change to enable more men to get diagnosed earlier, and stop them getting the news I got.' One option is a PSA blood test which checks the level of prostate-specific antigens in the blood, A high reading may be a sign of a prostate condition. NHS guidance says these tests are not routinely used as they are not reliable, but men over 50 can ask GPs for one. Sir Chris's comments came after Prostate Cancer UK urged the UK Government for an overhaul of NHS guidelines to encourage GPs to proactively speak to men at high risk from 45 years old. #ProstateCancer has become the most common cancer in England. However, for a disease that affects 1 in 8 men, there's still no screening programme and outdated NHS guidelines prevent lifesaving conversations with men at highest risk. ➡️ Read more: — Prostate Cancer UK (@ProstateUK) January 28, 2025 According to the charity, around one in eight men in the UK will get prostate cancer, which occurs when cells in the prostate start to grow in an uncontrolled way and, if not detected early, risks spreading. Sir Chris added: 'I believe men at highest risk, for example men with a family history like me or black men, should be contacted by their GP earlier on to discuss a simple PSA blood test that can check for signs of prostate cancer. Then if there are any issues, they can get it treated it at an earlier stage. 'I've told my story to help raise awareness about the most common cancer in men and get more thinking about their risk and what they can do, but it shouldn't all be men's responsibility. 'I've faced many challenges in my life, and going public with my prostate cancer diagnosis was certainly one of them. 'I've been incredibly lucky to have so much support from my family, friends and the general public. The kindness has lifted me up and given me a sense of purpose, and I'm committed to taking that forward and using my platform to raise awareness of the most common cancer in men and help more men at risk to come forward and get tested.' The Scottish cyclist has launched his own charity cycling challenge, Tour de 4, with the aim of changing perceptions around stage four cancer. The challenge will take place on September 7 in Glasgow with a final registration phase open for riders to sign up. Speaking about Sir Chris, Laura Kerby, chief executive at Prostate Cancer UK, said: 'His bravery and tireless work to raise awareness has already made a huge impact. 'In just a few months after Sir Chris went public with his diagnosis last year, over 286,000 people used our online risk checker to learn more about the disease, find out their own risk and learn what they can choose to do about it. 'His bravery has inspired so many men to take action, and he has undoubtedly saved lives. 'One in eight men will get prostate cancer. The earlier it's found, the easier it is to treat — but there's currently no screening programme in the UK. So if, like Sir Chris, you have a family history of the disease, or if you're black, we strongly encourage you to speak to your GP about testing from the age of 45. 'We don't think it's right that the responsibility is all on men's shoulders, so we're calling on the Health Secretary to overhaul outdated NHS guidelines so that GPs are empowered to actually start conversations with these men at highest risk.' A Government spokesperson said: 'This Government has been clear we would like to see screening in place but the decision must be evidence-led, which is why the UK National Screening Committee is looking at this as a priority – including reviewing the evidence for screening men with a family history of prostate cancer. 'While the review is taking place we are getting on with improving cancer treatment and prevention, as well as funding tens of millions of pounds of research.'
Rhyl Journal
an hour ago
- Rhyl Journal
Chris Hoy calls for systemic change in testing for prostate cancer
The 49-year old cyclist was diagnosed with stage four prostate cancer in 2023 and was told last year that it has spread to his bones and is terminal. NHS guidance says men over the age of 50 are at highest risk of developing prostate cancer, but Sir Chris wants to help men get screened earlier. He said: 'I was diagnosed with stage four prostate cancer at 47. By this age, my prostate cancer was advanced and could have been progressing from when I was 45 or even younger. 'With prostate cancer, the earlier you find it, the easier it is to treat. We need the system to change to enable more men to get diagnosed earlier, and stop them getting the news I got.' One option is a PSA blood test which checks the level of prostate-specific antigens in the blood, A high reading may be a sign of a prostate condition. NHS guidance says these tests are not routinely used as they are not reliable, but men over 50 can ask GPs for one. Sir Chris's comments came after Prostate Cancer UK urged the UK Government for an overhaul of NHS guidelines to encourage GPs to proactively speak to men at high risk from 45 years old. #ProstateCancer has become the most common cancer in England. However, for a disease that affects 1 in 8 men, there's still no screening programme and outdated NHS guidelines prevent lifesaving conversations with men at highest risk. ➡️ Read more: — Prostate Cancer UK (@ProstateUK) January 28, 2025 According to the charity, around one in eight men in the UK will get prostate cancer, which occurs when cells in the prostate start to grow in an uncontrolled way and, if not detected early, risks spreading. Sir Chris added: 'I believe men at highest risk, for example men with a family history like me or black men, should be contacted by their GP earlier on to discuss a simple PSA blood test that can check for signs of prostate cancer. Then if there are any issues, they can get it treated it at an earlier stage. 'I've told my story to help raise awareness about the most common cancer in men and get more thinking about their risk and what they can do, but it shouldn't all be men's responsibility. 'I've faced many challenges in my life, and going public with my prostate cancer diagnosis was certainly one of them. 'I've been incredibly lucky to have so much support from my family, friends and the general public. The kindness has lifted me up and given me a sense of purpose, and I'm committed to taking that forward and using my platform to raise awareness of the most common cancer in men and help more men at risk to come forward and get tested.' The Scottish cyclist has launched his own charity cycling challenge, Tour de 4, with the aim of changing perceptions around stage four cancer. The challenge will take place on September 7 in Glasgow with a final registration phase open for riders to sign up. Speaking about Sir Chris, Laura Kerby, chief executive at Prostate Cancer UK, said: 'His bravery and tireless work to raise awareness has already made a huge impact. 'In just a few months after Sir Chris went public with his diagnosis last year, over 286,000 people used our online risk checker to learn more about the disease, find out their own risk and learn what they can choose to do about it. 'His bravery has inspired so many men to take action, and he has undoubtedly saved lives. 'One in eight men will get prostate cancer. The earlier it's found, the easier it is to treat — but there's currently no screening programme in the UK. So if, like Sir Chris, you have a family history of the disease, or if you're black, we strongly encourage you to speak to your GP about testing from the age of 45. 'We don't think it's right that the responsibility is all on men's shoulders, so we're calling on the Health Secretary to overhaul outdated NHS guidelines so that GPs are empowered to actually start conversations with these men at highest risk.' A Government spokesperson said: 'This Government has been clear we would like to see screening in place but the decision must be evidence-led, which is why the UK National Screening Committee is looking at this as a priority – including reviewing the evidence for screening men with a family history of prostate cancer. 'While the review is taking place we are getting on with improving cancer treatment and prevention, as well as funding tens of millions of pounds of research.'
Rhyl Journal
an hour ago
- Rhyl Journal
ADHD waiting list led to rise in unregulated private providers
The ADHD taskforce, commissioned by NHS England with the support of the Government, has published an interim report saying the system for diagnosing and managing ADHD needs to be overhauled. At the moment, ADHD assessment and treatment in England is provided by highly specialised doctors in secondary care. But the report warned: 'Inability to access NHS services has led to a significant growth in the use of private providers that are not regulated, resulting in two-tier access to services, diagnosis and treatment; one for those who can pay and another for those who cannot. 'This drives health inequalities and links to disproportionate impacts and outcomes in the education and justice systems, employment and health.' Experts behind the study said waiting times for NHS ADHD services 'have escalated and are unacceptably long' and demand on services is 'very likely' to continue to rise. The taskforce concluded that ADHD is not solely the remit of the NHS and other health providers, with schools being vital for identifying and meeting needs at an early stage. And while a clinical diagnosis of ADHD via the NHS is required if a person needs medication, early support can still be provided to others. The report said: 'We need timely recognition and early support of suspected ADHD and neurodivergence across all settings. 'This is especially important in schools and the early years, to prevent adverse impacts and costly outcomes in the future. This should be needs-led and not require a clinical diagnosis.' The report also suggested there is no evidence of over-diagnosis of ADHD in the UK. It argued: 'England and the rest of the UK have much lower service recognition and treatment rates of ADHD diagnosis compared with other European countries. 'Recent data show a very high level of under-recognition and under-treatment of strictly diagnosed ADHD, with significant inequalities in access to care.' The report also addressed concerns about potential 'over-medicalisation and over-diagnosis', including worries that people are self-diagnosing ADHD based on information from social media. However, the report, said that 'currently there is no good evidence on what percentage of those waiting to see a clinician have self-diagnosed ADHD using social media and eventually meet or do not meet ADHD diagnostic criteria after a high-quality assessment. 'We only know currently that in England, recognised rates of ADHD are lower than the expected prevalence of ADHD.' Currently, the estimated economic costs of not treating ADHD are around £17 billion to the UK economy, the report went on. This includes through lower tax contributions, people needing state benefits and more likely to be not in education, employment or training, or who are long-term unemployed. 'Many of these costs are avoidable, as with appropriate, early support, people with ADHD can thrive,' it said. Professor Anita Thapar, chair of the ADHD Taskforce, said: 'The recommendations put forward by the taskforce will require action across Government and cross-sector organisations to make the necessary changes to improve the lives of people with ADHD. 'We need to get this right, to make sure people get early diagnosis and support, not just in the NHS but across society.' Dr Adrian James, NHS England's medical director for mental health and neurodiversity, said: 'We know that too many people with ADHD have been waiting for too long for support, which is why we launched the taskforce last year to help respond to the significant growth in the need for care. 'It is clear that much more needs to be done to improve ADHD assessment and care in England and ensure people can get a timely diagnosis, and we welcome the findings from the interim report, and look forward to its final conclusions later this year.' A Department of Health and Social Care spokesperson said: 'Lord Darzi's report into the state of the NHS laid out how severe the delays have become for people waiting for an attention deficit hyperactivity disorder diagnosis. 'We welcome the publication of the ADHD Taskforce's interim report, which provides valuable insights into the challenges affecting those with ADHD, including access to services and support.' The NHS has launched publicly-available data collection on ADHD referrals and waiting times to help local teams better understand how they are performing. By March 2026, the Government also aims for six in 10 pupils to have access to a mental health support team in school.
